Search Results
Oct 31, 2025, 07:00 ET Charter Announces Third Quarter 2025 Results
to or when they become due and to fund our operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets; our ability to comply with all covenants in our indentures and credit facilities,
More news about: Charter Communications, Inc.
Oct 31, 2025, 06:30 ET Xenia Hotels & Resorts Reports Third Quarter 2025 Results
such outbreaks, weather and climate-related events, such as hurricanes, tornadoes, floods, wildfires, and droughts, and natural or man-made disasters; (iii) inflation and inflationary pressures which increases labor costs and other costs of providing services to guests and complying with hotel brand standards,
More news about: Xenia Hotels & Resorts, Inc.
Oct 31, 2025, 04:47 ET SalsSky: The Chosen One -- The Revolutionary System Redefining Life Transformation and Personal Growth
+1 Connect (Connection): Accelerate growth through mentorship, accountability, and a high-vibration global network. Level III – Talk to STAR (Respect): Real-time breakthrough sessions for deep emotional alignment and practical clarity. Level IV – Become
More news about: SalsSky
Oct 31, 2025, 04:00 ET Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
three-month daily dosing regimen, with few adverse events (AEs) reported Results support progressing VES001 into Phase IIb/III trials in people with FTD-GRN, the variant of FTD caused by genetically low progranulin levels
More news about: Vesper Bio
Oct 30, 2025, 20:48 ET KIA ANNOUNCES PRICING FOR 2026 NIRO HEV
with options, driving conditions, driving habits and your vehicle's condition. iii Advanced driver assistance systems are not substitutes for safe driving and may not detect all objects around the vehicle.
More news about: Kia America
Oct 30, 2025, 16:50 ET LEIFRAS Co., Ltd. Reports Financial Results of Six Months Ended June 30, 2025
preparation for our initial public offering ("IPO"), (ii) the increase in promotion fees of JPY10.7 million ($0.07 million) due to business expansion, (iii) the increase in office rental fees of JPY12.6 million ($0.09 million) due to business expansion, (iv) the increase in system maintenance fee expenses
More news about: LEIFRAS Co., Ltd.
Oct 30, 2025, 16:30 ET Select Medical Holdings Corporation Announces Results For Its Third Quarter Ended September 30, 2025 and Cash Dividend
Refer to table III for calculation of earnings per common share.
More news about: Select Medical Holdings Corporation
Oct 30, 2025, 16:30 ET QUAKER HOUGHTON ANNOUNCES THIRD QUARTER 2025 RESULTS
The Company's third quarter and nine months of 2025 operating performance for each of its three reportable segments: (i) Americas; (ii) EMEA; and (iii) Asia/Pacific, is further described below.
More news about: Quaker Chemical Corporation
Oct 30, 2025, 16:30 ET RE/MAX HOLDINGS, INC. REPORTS THIRD QUARTER 2025 RESULTS
organic revenue growth as revenue growth from continuing operations excluding (i) revenue from Marketing Funds, (ii) revenue from acquisitions, and (iii) the impact of foreign currency movements. The Company defines revenue from acquisitions as the revenue generated from the date of an acquisition to
More news about: RE/MAX Holdings, Inc.
Oct 30, 2025, 16:15 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
(ii) 1,060,574 total outstanding common shares, par value CHF 0.05, issuable upon the exercise of pre-funded warrants issued as Merger consideration, (iii) 13,778 preferred shares, par value CHF 0.05 issued and outstanding, and (iv) 58,320 preferred participation certificates, par value CHF 0.05 issued
More news about: NewCelX Ltd.; NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 30, 2025, 16:13 ET JOHN HANCOCK ANNOUNCES PORTFOLIO MANAGER CHANGES FOR JOHN HANCOCK CLOSED-END FUNDS
Preferred Income Fund III, John Hancock Premium Dividend Fund and John Hancock Tax-Advantaged Dividend Income Fund. Joseph H. Bozoyan, CFA and James Gearhart, CFA, will continue to serve as portfolio managers to Preferred Income Fund, Preferred Income Fund II, Preferred Income Fund III, John Hancock Premium
More news about: John Hancock Investment Management
Oct 30, 2025, 16:05 ET Alexander & Baldwin, Inc. Reports Third Quarter 2025 Results
calculation or estimation of certain reconciling items, including but not limited to, (i) occupancy changes; (ii) terms for new and renewal leases; (iii) collections from tenants; and (iv) other nonrecurring/unplanned income or expense items. These items are inherently uncertain and depend on various
More news about: Alexander & Baldwin
Oct 30, 2025, 16:05 ET Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) the completion of the proposed acquisition of SomaLogic, Inc.
More news about: Illumina, Inc.
Oct 30, 2025, 16:02 ET COLUMBIA BANKING SYSTEM, INC. REPORTS THIRD QUARTER 2025 RESULTS
cost savings and any revenue or expense synergies from the Transaction may not be fully realized or may take longer than anticipated to be realized, (iii) deposit attrition, customer or employee loss, and/or revenue loss as a result of the Transaction, and (iv) shareholder litigation that could negatively
More news about: Columbia Banking System, Inc.
Oct 30, 2025, 16:01 ET Coveo Reports Second Quarter Fiscal 2026 Financial Results
Adjusted Product Gross Profit, and Adjusted Professional Services Gross Profit (collectively referred to as our "Adjusted Gross Profit Measures"); (iii) Adjusted Gross Margin, Adjusted Product Gross Margin, and Adjusted Professional Services Gross Margin (collectively referred to as our "Adjusted Gross
More news about: Coveo Solutions Inc.
Oct 30, 2025, 15:00 ET GTIS Brazil Fund lidera o Ranking de Sustentabilidade da GRESB na América Latina
em sua categoria no Global Real Estate Sustainability Benchmark ("GRESB") 2025, pelo décimo ano, com 91 pontos de 100. O GTIS Brazil Real Estate Fund III ficou em segundo lugar, também com 91 pontos. Os dois fundos ocuparam, respectivamente, a primeira e a segunda posição em um benchmark composto por 43
More news about: GTIS
Oct 30, 2025, 12:45 ET Universal Music Group N.V. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2025
amortization of intangible assets; ii. impairment losses on goodwill and other intangibles; iii. depreciation of tangible assets including right of use assets; iv. (gains)/losses on the sale of tangible
More news about: Universal Music Group N.V.
Oct 30, 2025, 12:45 ET Universal Music Group N.V. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2025
amortization of intangible assets; ii. impairment losses on goodwill and other intangibles; iii. depreciation of tangible assets including right of use assets; iv. (gains)/losses on the sale of tangible
More news about: Universal Music Group N.V.
Oct 30, 2025, 11:34 ET THE REPUBLIC OF SURINAME HEREBY ANNOUNCES AN EXTENSION OF THE INVITATION FOR OFFERS TO TENDER FOR CASH ITS 7.95% CASH/PIK SECURITIES DUE 2033
Order"), (ii) who fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) who are outside the UK, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of
More news about: The Republic of Suriname
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS). This marks ivonescimab's first final OS analysis in a Phase III trial
More news about: Akeso, Inc.
Oct 30, 2025, 09:00 ET CULLEN/FROST REPORTS THIRD QUARTER RESULTS
of 2025 were 14.14 percent, 14.59 percent and 16.04 percent, respectively, and continue to be in excess of well-capitalized levels and exceed Basel III minimum requirements. Net interest income on a taxable-equivalent basis was $463.7 million for the third quarter of 2025,
More news about: Cullen/Frost Bankers, Inc.
Oct 30, 2025, 08:45 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: The Gross Law Firm
Oct 30, 2025, 08:45 ET FLR LAWSUIT ALERT: The Gross Law Firm Notifies Fluor Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: The Gross Law Firm
Oct 30, 2025, 08:15 ET DIAMOND HILL INVESTMENT GROUP, INC. REPORTS RESULTS FOR THIRD QUARTER 2025 AND DECLARES QUARTERLY AND SPECIAL DIVIDEND
are not limited to: (i) any reduction in the Company's AUM or AUA; (ii) withdrawal, renegotiation, or termination of investment advisory agreements; (iii) damage to the Company's reputation; (iv) failure to comply with investment guidelines or other contractual requirements; (v) challenges from the competition
More news about: Diamond Hill Investment Group, Inc.
Oct 30, 2025, 08:00 ET Mallinckrodt to Present Data on Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at Kidney Week 2025
and Time: Friday, November 7, 2025; 10:00 a.m. – 12:00 p.m. CT This post hoc analysis of the Phase III CONFIRM clinical trial assessed the impact of paracentesis, a procedure to help relieve intra-abdominal pressure which may improve renal hemodynamics,
More news about: Mallinckrodt plc